Volunteer Login Study Team Login

Print

Lay Description

The name of this trial is MissionAD1. This 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to Alzheimer's Disease (AD)/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety of elenbecestat (proposed international nonproprietary name [INN]) (E2609).

Category

  • Inflammatory Diseases
IRB Number
20180093HU
NCT Number
ct.gov registration not required
Open to Enrollment
Yes

Eligibility

Eligible Ages
50 Years - 85 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

Exclusion Criteria

Study Design

Study Contact


Regulatory Point of Contact
Elizabeth Coss
(210) 567-4876
cosse@uthscsa.edu

Principal Investigator
Elizabeth Coss